CAMBRIDGE, England & BAD HOMBURG, Germany--(BUSINESS WIRE)--Cellular Origins and Fresenius Kabi, an operating company of Fresenius, announce today they have signed a development agreement that ...

A study led by the School of Engineering of the Hong Kong University of Science and Technology (HKUST) has developed an innovative method that overcomes the limitations of traditional additive ...

Chimeric antigen receptor (CAR) T-cell therapy has revolutionized treatment for non-responsive or relapsing hematological malignancies, providing an intensive, personalized form of immunotherapy. It ...

Cellular manufacturing systems (CMS) represent a pivotal approach to modern industrial production, in which machines and workstations are organised into discrete cells dedicated to the manufacture of ...

Cellular Origins, a TTP Company focused on enabling scalable, cost-effective, and efficient manufacture of cell and gene therapies (CGTs), and the Cell and Gene Therapy Catapult (CGT Catapult), an ...

SEAL BEACH, Calif. & SAN DIEGO--(BUSINESS WIRE)--Dendreon Pharmaceuticals, a commercial-stage biopharmaceutical company and pioneer in the development of cellular immunotherapy, and Shoreline ...

For some cases of cancer, the starting point of a new treatment is already inside the patient. Cell therapy provides another option for advanced blood cancers that have not responded to other drugs.

Zachary Sun, PhD, co-founder and CSO of Tierra Biosciences, spoke last year at SynBioBeta about cell-free protein synthesis. He and Mike Nemzek, CEO of Tierra, speak to GEN about the potential for ...

Cellular Origins and Fresenius Kabi, an operating company of Fresenius, announce today they have signed a development agreement that leverages each company’s expertise in cell and gene therapies (CGTs ...